logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.

    • beta Lactamase Inhibitor class drugs

    FiltersReset Filters
    12 results

    • ampicillin and sulbactam

      (Ampicillin sodium and Sulbactam sodium)
      Hospira, Inc
      Usage: Ampicillin and sulbactam for injection is indicated for treating infections caused by susceptible strains in skin, intra-abdominal, and gynecological infections. It targets beta-lactamase producing organisms and can also be used for mixed infections involving ampicillin-susceptible bacteria, following appropriate culture and susceptibility testing.

    • ampicillin and sulbactam

      (Ampicillin Sodium and Sulbactam Sodium)
      Eugia US LLC
      Usage: Ampicillin and sulbactam for injection is indicated for treating infections from susceptible microorganisms in skin and skin structure infections, intra-abdominal infections, and gynecological infections. It is effective against beta-lactamase producing strains of various bacteria, while also addressing mixed infections involving ampicillin-susceptible organisms.

    • ampicillin sodium and sulbactam sodium

      (ampicillin sodium, sulbactam sodium)
      Armas Pharmaceuticals Inc.
      Usage: Ampicillin and sulbactam for injection is indicated for treating skin and skin structure infections, intra-abdominal infections, and gynecological infections caused by beta-lactamase producing organisms, including specific strains of Escherichia coli, Klebsiella, Bacteroides, and others. It is also effective against ampicillin-susceptible organisms.

    • avycaz

      (ceftazidime, avibactam)
      Allergan, Inc.
      Usage: AVYCAZ (ceftazidime and avibactam) is indicated for treating complicated intra-abdominal and urinary tract infections, including pyelonephritis, as well as hospital-acquired and ventilator-associated bacterial pneumonia. It targets susceptible gram-negative bacteria in adult and pediatric patients (≥31 weeks gestational age).

    • piperacillin and tazobactam

      (piperacillin and tazobactam)
      Armas Pharmaceuticals Inc.
      Usage: Piperacillin and tazobactam is indicated for treating intra-abdominal infections, nosocomial pneumonia, skin and skin structure infections, female pelvic infections, and moderate community-acquired pneumonia in adults and pediatric patients (2 months and older), specifically targeting beta-lactamase producing bacteria.

    • piperacillin and tazobactam

      (Piperacillin and Tazobactam)
      Sandoz Inc
      Usage: Piperacillin and tazobactam for injection is indicated for treating intra-abdominal infections, nosocomial pneumonia, skin infections, female pelvic infections, and community-acquired pneumonia in patients aged 2 months and older. It targets infections caused by beta-lactamase producing bacteria, aiming to reduce drug resistance.

    • piperacillin and tazobactam

      (Piperacillin and Tazobactam)
      Hospira, Inc
      Usage: Piperacillin and tazobactam is indicated for treating intra-abdominal infections, nosocomial pneumonia, skin and skin structure infections, female pelvic infections, and moderate community-acquired pneumonia in adults and pediatric patients (2 months and older), specifically caused by beta-lactamase producing bacteria.

    • piperacillin and tazobactam

      (piperacillin and tazobactam)
      Armas Pharmaceuticals Inc.
      Usage: Piperacillin and tazobactam is indicated for treating intra-abdominal and nosocomial pneumonia in adults and pediatric patients, as well as skin infections, female pelvic infections, and moderate community-acquired pneumonia, particularly when caused by specific beta-lactamase producing bacteria. It should be used judiciously to prevent drug resistance.

    • piperacillin and tazobactam

      (piperacillin sodium and tazobactam sodium)
      Civica, Inc.
      Usage: Piperacillin and tazobactam is indicated for treating intra-abdominal infections, nosocomial pneumonia, skin infections, female pelvic infections, and community-acquired pneumonia in patients 2 months and older, specifically those caused by beta-lactamase producing bacteria. It aims to reduce drug-resistant bacteria development.

    • vabomere

      (Meropenem-Vaborbactam)
      Melinta Therapeutics, LLC
      Usage: VABOMERE® is indicated for treating complicated urinary tract infections (cUTI), including pyelonephritis, in patients 18 and older, caused by susceptible bacteria such as E. coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex. It aims to reduce drug-resistant bacteria development.